Status:
COMPLETED
18F-FDG PET Radiomics of Diffuse Large B-cell Lymphoma
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions:
Lymphoma, Large B-Cell, Diffuse
Eligibility:
All Genders
18+ years
Brief Summary
This study aims to investigate the prognostic value of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) radiomics in diffuse large B-cell lymphoma (DLBCL) and its additional value t...
Detailed Description
Several studies have shown that 18F-FDG PET radiomics is predictive of survival in DLBCL. However, to the best of the investigator's knowledge, a multi-feature radiomic signature for prognosis assessm...
Eligibility Criteria
Inclusion
- histopathologically confirmed diffuse large B-cell lymphoma (DLBCL);
- Over 18 years old when diagnosed;
- Have undergone pre-treatment 18F-FDG PET/CT;
- Have been initially treated with the combination of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) or R-EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin).
Exclusion
- Have primary central nervous system (CNS) lymphoma or second primary cancer;
- Have undergone surgical resection;
- With an incomplete follow-up.
Key Trial Info
Start Date :
April 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 30 2021
Estimated Enrollment :
152 Patients enrolled
Trial Details
Trial ID
NCT04317313
Start Date
April 1 2020
End Date
July 30 2021
Last Update
October 21 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Second Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, China, 310009